Skip to main content
TME Pharma N.V. logo

TME Pharma N.V. — Investor Relations & Filings

Ticker · ALTME ISIN · NL0015000YE1 LEI · 724500EPNADXWZ58U595 Euronext Growth Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2026-05-21 Proxy Solicitation & In…
Country NL Netherlands
Listing Euronext Growth ALTME

About TME Pharma N.V.

https://www.tmepharma.com/

TME Pharma N.V. is a clinical-stage biotechnology company developing novel therapies for aggressive cancers by targeting the tumor microenvironment (TME). The company's proprietary technology focuses on neutralizing chemokines within the TME to break down the tumor's protective barriers and inhibit its repair mechanisms. This approach is designed to work in combination with other treatments, such as radiotherapy and immunotherapy, to enhance their therapeutic impact. TME Pharma's lead clinical programs are concentrated on difficult-to-treat cancers, including glioblastoma and pancreatic cancer. Its lead candidate, NOX-A12, has shown promising results in clinical trials for glioblastoma, demonstrating a statistically significant improvement in patient survival when combined with standard-of-care therapies.

Recent filings

Filing Released Lang Actions
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal convocation notice for the 2026 Annual General Meeting, including the agenda, proposals (approval of 2025 accounts, board appointments), voting instructions, and details on how shareholders may participate or vote by proxy. This falls under ‘Proxy Solicitation & Information Statement’ (materials sent to shareholders to provide information and request votes for meetings) rather than presentation materials (AGM-R) or a simple publication announcement (RPA).
2026-05-21 English
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026
Proxy Solicitation & Information Statement Classification · 83% confidence The document is a formal convocation notice for the 2026 Annual General Meeting of shareholders, detailing the meeting date, agenda items (including approval of annual accounts and board nominations), proxy voting instructions, and where to find the explanatory materials. This aligns with a Proxy Solicitation & Information Statement, which comprises materials sent to shareholders to provide information and request votes for meetings.
2026-05-21 French
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS ANNUELS ET SON RAPPORT ANNUEL
Annual Report Classification · 95% confidence The document is a detailed announcement of TME Pharma's annual financial results for the fiscal year ending December 31, 2025, including financial figures such as net loss, equity status, cash position, and strategic outlook. It explicitly mentions the annual report for 2025 approved by management and supervisory board and available on the company's website. The content includes comprehensive financial data, business strategy, and management commentary, which aligns with the characteristics of an Annual Report (10-K equivalent). The document is 7,439 characters long, which is sufficient to contain substantive financial information rather than just an announcement or a brief summary. Therefore, it should be classified as an Annual Report (10-K). FY 2025
2026-04-30 French
TME Pharma publishes its annual financial results and annual report
Annual Report Classification · 95% confidence The document is titled as an announcement of TME Pharma's annual financial results and annual report for the fiscal year ending December 31, 2025. It includes a financial summary with figures such as cash resources, net loss, and equity, as well as an outlook for 2026. The text mentions that the Annual Report 2025 has been approved by management and supervisory boards and is available on the company's website. The document contains substantive financial data and analysis, not just a brief announcement or a link to the report. The length of the document (6458 characters) supports it being a full report rather than a short announcement. Therefore, this document fits the definition of an Annual Report (10-K) rather than a Report Publication Announcement (RPA) or Regulatory Filing (RNS). FY 2025
2026-04-30 English
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12
Regulatory Filings Classification · 60% confidence The text is a corporate press release announcing the publication of clinical trial results in the journal Nature Communications. It is not a formal financial report (e.g., 10-K, quarterly report), not an earnings release, not a capital-markets transaction, not board changes, not a proxy statement, etc. It does not match any of the specialized categories, so it falls into the general regulatory announcement/fallback category: RNS.
2026-04-16 French
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing the publication of a scientific article in Nature Communications, not a financial report, earnings release, call transcript, regulatory vote, or management change. It does not present financial statements or attached regulatory filings; it is a general investor/market announcement. This falls into the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as RNS.
2026-04-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.